Rezolute Inc (RZLT)

$3.84 -0.11 (-2.78%)
Market Cap 369.76M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,527,300
Avg Vol 1,368,444
Day's Range N/A - N/A
Shares Out 96.29M
Stochastic %K 20%
Beta 0.60
Analysts Strong Sell
Price Target $7.67

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
KONGLIVES1
KONGLIVES1 Sep. 19 at 4:27 PM
$RZLT people are getting tired of waiting
0 · Reply
Cello69
Cello69 Sep. 18 at 6:20 PM
$RZLT Did the rat die????
0 · Reply
oaksapollo
oaksapollo Sep. 18 at 4:48 PM
$RZLT Wow the market really doesn't like them skipping out on earnings.
0 · Reply
Cello69
Cello69 Sep. 18 at 4:10 PM
$RZLT Dead ?
0 · Reply
Monty3030
Monty3030 Sep. 17 at 10:44 PM
$RZLT Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M!! 🤯🤯 How much will CHI & Tumor HI go for it approved... Wow!!
0 · Reply
Monty3030
Monty3030 Sep. 17 at 10:39 PM
$RZLT This is good news. Maybe RZLT is next!
0 · Reply
oaksapollo
oaksapollo Sep. 17 at 8:41 PM
$RZLT ok something is going on here. Historical earnings releases for full fiscal year: Wed 9/17/25 Thur 9/19/24 Thur 9/14/23 Thur 9/15/22 Wed 9/15/21 You get the idea, always a Wed/Thur mid-September. Nothing yesterday, nothing today. I believe their deadline is 9/28, so they have time before they are forced to file. Most likely they are hoping for FDA feedback prior to updating?
1 · Reply
oaksapollo
oaksapollo Sep. 17 at 2:50 PM
$RZLT Now thinkorswim saying earnings today. I think nobody knows? But maybe that's a good sign, perhaps they are trying to include some type of substantial FDA update into their PR.
0 · Reply
Brznx
Brznx Sep. 16 at 8:04 PM
$RZLT 3.5$ tommorow
0 · Reply
Krenk
Krenk Sep. 16 at 5:28 PM
$RZLT im in 🤯
0 · Reply
Latest News on RZLT
Rezolute provides update on FDA review of sunRIZE study

2026-09-09T11:41:01.000Z - 11 days ago

Rezolute provides update on FDA review of sunRIZE study

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Sep 9, 2026, 7:00 AM EDT - 11 days ago

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute to Participate in Upcoming Investor Conferences

Sep 2, 2026, 7:30 AM EDT - 18 days ago

Rezolute to Participate in Upcoming Investor Conferences

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Jul 21, 2026, 7:30 AM EDT - 2 months ago

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Slides: Corporate presentation

Jun 26, 2026, 7:00 AM EDT - 2 months ago

Rezolute Slides: Corporate presentation

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Jun 17, 2026, 7:00 AM EDT - 3 months ago

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Rezolute price target raised to $11, named a Best Idea at Guggenheim

2026-06-15T10:41:18.000Z - 3 months ago

Rezolute price target raised to $11, named a Best Idea at Guggenheim

Rezolute Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 3:45 PM EDT - 3 months ago

Rezolute Transcript: Jefferies Global Healthcare Conference 2026

Rezolute Slides: FY 2026

Jun 4, 2026, 3:45 PM EDT - 3 months ago

Rezolute Slides: FY 2026

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Jun 4, 2026, 7:30 AM EDT - 3 months ago

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Rezolute price target raised to $14 from $10 at Maxim

2026-06-03T15:04:08.000Z - 3 months ago

Rezolute price target raised to $14 from $10 at Maxim

Rezolute price target raised to $6 from $5 at Wedbush

2026-06-03T12:16:54.000Z - 3 months ago

Rezolute price target raised to $6 from $5 at Wedbush

Rezolute upgraded to Outperform from Market Perform at Citizens

2026-06-03T08:36:37.000Z - 3 months ago

Rezolute upgraded to Outperform from Market Perform at Citizens

Rezolute price target raised to $6 from $5 at BTIG

2026-06-02T19:55:11.000Z - 3 months ago

Rezolute price target raised to $6 from $5 at BTIG

Rezolute price target raised to $14 from $10 at Maxim

2026-06-02T19:00:14.000Z - 3 months ago

Rezolute price target raised to $14 from $10 at Maxim

Rezolute provides interim update on ersodetug study

2026-06-02T11:31:37.000Z - 3 months ago

Rezolute provides interim update on ersodetug study

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Jun 2, 2026, 7:00 AM EDT - 3 months ago

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute price target raised to $10 from $4 at Maxim

2026-05-14T14:28:58.000Z - 4 months ago

Rezolute price target raised to $10 from $4 at Maxim

Rezolute reports Q3 EPS (16c), consensus (17c)

2026-05-12T21:34:01.000Z - 4 months ago

Rezolute reports Q3 EPS (16c), consensus (17c)

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

May 12, 2026, 4:05 PM EDT - 4 months ago

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Earnings release: Q3 2026

May 12, 2026, 4:00 PM EDT - 4 months ago

Rezolute Earnings release: Q3 2026

Rezolute Quarterly report: Q3 2026

May 12, 2026, 4:00 PM EDT - 4 months ago

Rezolute Quarterly report: Q3 2026

Rezolute Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 4 months ago

Rezolute Slides: Corporate presentation

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

2026-05-01T16:21:30.000Z - 4 months ago

Rezolute presents results from Phase 3 sunRIZE study of ersodetug at PES 2026

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

May 1, 2026, 12:15 PM EDT - 4 months ago

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Rezolute, Inc. Investigated by the Portnoy Law Firm

Apr 24, 2026, 9:00 AM EDT - 4 months ago

Rezolute, Inc. Investigated by the Portnoy Law Firm

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Apr 21, 2026, 7:00 AM EDT - 5 months ago

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Rezolute Slides: Corporate presentation

Mar 30, 2026, 7:00 AM EDT - 5 months ago

Rezolute Slides: Corporate presentation

Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI

2026-03-25T10:46:08.000Z - 5 months ago

Wedbush upgrades Rezolute as worst case scenario seems unlikely for cHI

Rezolute upgraded to Outperform from Neutral at Wedbush

2026-03-25T10:37:36.000Z - 5 months ago

Rezolute upgraded to Outperform from Neutral at Wedbush

Rezolute provides update on sunRIZE study following Type B meeting with FDA

2026-03-24T11:26:35.000Z - 6 months ago

Rezolute provides update on sunRIZE study following Type B meeting with FDA

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Mar 24, 2026, 7:00 AM EDT - 6 months ago

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Rezolute to Participate in the Citizens Life Sciences Conference

Mar 4, 2026, 7:00 AM EST - 6 months ago

Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute management to meet with Maxim

2026-03-03T14:56:44.000Z - 6 months ago

Rezolute management to meet with Maxim

Rezolute reports Q2 EPS (22c), consensus (18c)

2026-02-12T21:16:42.000Z - 7 months ago

Rezolute reports Q2 EPS (22c), consensus (18c)

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Feb 12, 2026, 4:05 PM EST - 7 months ago

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Quarterly report: Q2 2026

Feb 12, 2026, 4:00 PM EST - 7 months ago

Rezolute Quarterly report: Q2 2026

Rezolute Earnings release: Q2 2026

Feb 12, 2026, 4:00 PM EST - 7 months ago

Rezolute Earnings release: Q2 2026

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:00 AM EST - 7 months ago

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute price target raised to $2 from $1 at Wedbush

2026-01-08T13:05:22.000Z - 8 months ago

Rezolute price target raised to $2 from $1 at Wedbush

Rezolute shares findings from Expanded Access Program in tumor HI

2026-01-07T12:17:20.000Z - 8 months ago

Rezolute shares findings from Expanded Access Program in tumor HI

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Jan 7, 2026, 7:00 AM EST - 8 months ago

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Rezolute Slides: Corporate Presentation

Jan 7, 2026, 7:00 AM EST - 8 months ago

Rezolute Slides: Corporate Presentation

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Dec 11, 2025, 2:39 PM EST - 9 months ago

Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT

Rezolute Transcript: Study Result

Dec 11, 2025, 8:30 AM EST - 9 months ago

Rezolute Transcript: Study Result

Rezolute Press release: Study Result

Dec 11, 2025, 8:30 AM EST - 9 months ago

Rezolute Press release: Study Result

Rezolute's rare disease drug fails main goal in late-stage trial

Dec 11, 2025, 7:05 AM EST - 9 months ago

Rezolute's rare disease drug fails main goal in late-stage trial

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Dec 11, 2025, 7:00 AM EST - 9 months ago

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute Transcript: AGM 2025

Nov 19, 2025, 6:00 PM EST - 10 months ago

Rezolute Transcript: AGM 2025

Rezolute Slides: Corporate Presentation

Nov 12, 2025, 7:00 AM EST - 10 months ago

Rezolute Slides: Corporate Presentation

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2025, 5:30 PM EST - 10 months ago

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rezolute Transcript: Status Update

Nov 10, 2025, 12:00 PM EST - 10 months ago

Rezolute Transcript: Status Update

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 10 months ago

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Quarterly report: Q1 2026

Nov 6, 2025, 4:00 PM EST - 10 months ago

Rezolute Quarterly report: Q1 2026

Rezolute Earnings release: Q1 2026

Nov 6, 2025, 4:00 PM EST - 10 months ago

Rezolute Earnings release: Q1 2026

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Nov 5, 2025, 7:30 AM EST - 10 months ago

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

KONGLIVES1
KONGLIVES1 Sep. 19 at 4:27 PM
$RZLT people are getting tired of waiting
0 · Reply
Cello69
Cello69 Sep. 18 at 6:20 PM
$RZLT Did the rat die????
0 · Reply
oaksapollo
oaksapollo Sep. 18 at 4:48 PM
$RZLT Wow the market really doesn't like them skipping out on earnings.
0 · Reply
Cello69
Cello69 Sep. 18 at 4:10 PM
$RZLT Dead ?
0 · Reply
Monty3030
Monty3030 Sep. 17 at 10:44 PM
$RZLT Ultragenyx Pharmaceutical Exec Says U.S. Per Patient Wholesale Acquisition Cost For Fayuvi Is Set At $3.95M!! 🤯🤯 How much will CHI & Tumor HI go for it approved... Wow!!
0 · Reply
Monty3030
Monty3030 Sep. 17 at 10:39 PM
$RZLT This is good news. Maybe RZLT is next!
0 · Reply
oaksapollo
oaksapollo Sep. 17 at 8:41 PM
$RZLT ok something is going on here. Historical earnings releases for full fiscal year: Wed 9/17/25 Thur 9/19/24 Thur 9/14/23 Thur 9/15/22 Wed 9/15/21 You get the idea, always a Wed/Thur mid-September. Nothing yesterday, nothing today. I believe their deadline is 9/28, so they have time before they are forced to file. Most likely they are hoping for FDA feedback prior to updating?
1 · Reply
oaksapollo
oaksapollo Sep. 17 at 2:50 PM
$RZLT Now thinkorswim saying earnings today. I think nobody knows? But maybe that's a good sign, perhaps they are trying to include some type of substantial FDA update into their PR.
0 · Reply
Brznx
Brznx Sep. 16 at 8:04 PM
$RZLT 3.5$ tommorow
0 · Reply
Krenk
Krenk Sep. 16 at 5:28 PM
$RZLT im in 🤯
0 · Reply
oaksapollo
oaksapollo Sep. 16 at 4:31 PM
$RZLT Should see "earnings" after hours today. Probably a non-event given that they just updated on the FDA situation.
1 · Reply
ezy123
ezy123 Sep. 14 at 3:30 PM
$RZLT What's going on with options?
1 · Reply
oaksapollo
oaksapollo Sep. 10 at 2:53 PM
$RZLT This and KYMR only green on my screen!
0 · Reply
FUD_Slayer
FUD_Slayer Sep. 10 at 12:28 PM
Posting this for myself to come back and see who has seen the most gains in 6 months Cheers bulls $OSTX $ALT $ICU $RZLT $RGNX
1 · Reply
KONGLIVES1
KONGLIVES1 Sep. 9 at 6:12 PM
$RZLT too many other places where I can take this money and put it to work. It’s getting close to pull the trigger. 
0 · Reply
oaksapollo
oaksapollo Sep. 9 at 1:11 PM
$RZLT wow great update guys. Love the way you keep talking about the OLE in vague terms without giving any real numbers. Inspires great confidence.
0 · Reply
Monty3030
Monty3030 Sep. 9 at 11:11 AM
$RZLT Update.... Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline 09/09/26 5:06 AM 7:06 AM EDT, September 09, 2026 (Benzinga Newswire) Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction in the use of background standard of care therapies Enrollment continues in the Phase 3 upLIFT study in tumor HI and the Company remains on track to report topline results before the end of 2026
1 · Reply
Monty3030
Monty3030 Sep. 9 at 8:18 AM
$RZLT 24.56 Days to Cover 25.18% Short Interest
0 · Reply
KONGLIVES1
KONGLIVES1 Sep. 8 at 1:24 PM
$RZLT patiently waiting 
0 · Reply
Monty3030
Monty3030 Sep. 4 at 2:58 PM
$RZLT Big call volume today for 9/18!!
0 · Reply
KONGLIVES1
KONGLIVES1 Sep. 3 at 3:59 PM
$RZLT please remember September is the month of the Titanic in the stock market 
0 · Reply
Monty3030
Monty3030 Sep. 3 at 11:24 AM
$RZLT 21.78 Days to Cover 25.18 Short Interest
0 · Reply